NIH R01 · 2025
PROJECT SUMMARY/ABSTRACT This project focuses on pioneering a novel approach in anti-cancer drug development through the creation and optimization of isoform-selective inhibitors targeting the 90 kDa heat shock protein (Hsp90β). Hsp90 is a crucial chaperone protein involved in the maturation of over 400 client proteins, many of which play significant roles in cancer progression. The selective inhibition of Hsp90β over other isoforms offers a promising strategy to mitigate the side effects associated with pan-Hsp90 inhibitors, such as ocular, cardio, and dose-escalating toxicities, which have hindered the clinical success of these treatments. The objectives of this research include the…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.